SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001144204-17-056236
Filing Date
2017-11-03
Accepted
2017-11-03 16:45:28
Documents
5
Period of Report
2017-10-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tv478555_8k.htm 8-K 26934
2 EXHIBIT 10.1 tv478555_ex10-1.htm EX-10.1 13995
3 EXHIBIT 10.2 tv478555_ex10-2.htm EX-10.2 126193
4 EXHIBIT 99.1 tv478555_ex99-1.htm EX-99.1 10033
5 GRAPHIC bcli_logo.jpg GRAPHIC 15043
  Complete submission text file 0001144204-17-056236.txt   199665
Mailing Address 3 UNIVERSITY PLAZA DRIVE SUITE 320 HACKENSACK NJ 07601
Business Address 3 UNIVERSITY PLAZA DRIVE SUITE 320 HACKENSACK NJ 07601 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

IRS No.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 171177077
SIC: 2836 Biological Products, (No Diagnostic Substances)